Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells

OncoImmunology

Volumn 5, Issue 4, 2016, Pages

  Otáhal, Pavel ^a,c   Průková, Dana ^b   Král, Vlastimil ^c   Fabry, Milan ^c   Vočková, Petra ^b   Latečková, Lucie ^b   Trněný, Marek ^a   Klener, Pavel ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

Chimeric antigenic receptor; lenalidomide; lymphoma; T cells; tumor immunotherapy

Indexed keywords

AIOLOS TRANSCRIPTION FACTOR; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; IKAROS TRANSCRIPTION FACTOR; LENALIDOMIDE; TRANSCRIPTION FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS (CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

EID: 84962812077     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1115940     Document Type: Article

References (25)

1. S.L.Maude, N.Frey, P.A.Shaw, R.Aplenc, D.M.Barrett, N.J.Bunin, A.Chew, V.E.Gonzalez, Z.Zheng, S.F.Lacey et al., Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
2. J.Maher. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012; 2012:278093; PMID:23304553; http://dx.doi.org/10.5402/2012/278093
3. K.J.Curran, B.A.Seinstra, Y.Nikhamin, R.Yeh, Y.Usachenko, D.G.van Leeuwen, T.Purdon, H.J.Pegram, R.J.Brentjens. Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression. Mol Ther 2015; 23(4):769-78; PMID:25582824; http://dx.doi.org/10.1038/mt.2015.4
4. E.Q.Han, X.L.Li, C.R.Wang, T.F.Li, S.Y.Han. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; PMID:24353912; http://dx.doi.org/10.1186/1756-8722-6-47
5. L.B.John, M.H.Kershaw, P.K.Darcy. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013; 2(10):e26286; PMID:24353912; http://dx.doi.org/10.4161/onci.26286
6. C.Heise, T.Carter, P.Schafer, R.Chopra. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes. Expert Rev Anticancer Ther 2010; 10 (10):1663-72; PMID:20942636; http://dx.doi.org/10.1586/era.10.135
7. J.Kronke, N.D.Udeshi, A.Narla, P.Grauman, S.N.Hurst, M.McConkey, T.Svinkina, D.Heckl, E.Comer, X.Li et al., Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343(6168): 301-5; PMID:24292625; http://dx.doi.org/10.1126/science.1244851
8. A.K.Gandhi, J.Kang, C.G.Havens, T.Conklin, Y.Ning, L.Wu, T.Ito, H.Ando, M.F.Waldman, A.Thakurta et al., Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014; 164(6):811-21; PMID:24328678; http://dx.doi.org/10.1111/bjh.12708
9. R.LeBlanc, T.Hideshima, L.P.Catley, R.Shringarpure, R.Burger, N.Mitsiades, C.Mitsiades, P.Cheema, D.Chauhan, P.G.Richardson et al., Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103(5):1787-90; PMID:14512311; http://dx.doi.org/10.1182/blood-2003-02-0361
10. P.H.Schafer, A.K.Gandhi, M.A.Loveland, R.S.Chen, H.W.Man, P.P.Schnetkamp, G.Wolbring, S.Govinda, L.G.Corral, F.Payvandi et al., Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305(3):1222-32; PMID:12649301; http://dx.doi.org/10.1124/jpet.102.048496
11. P.A.Haslett, L.G.Corral, M.Albert, G.Kaplan. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187(11):1885-92; PMID:9607928; http://dx.doi.org/10.1084/jem.187.11.1885
12. M.Klanova, T.Soukup, R.Jaksa, J.Molinsky, L.Lateckova, B.C.Maswabi, D.Prukova, J.Brezinova, K.Michalova, P.Vockova et al., Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. Lab Invest 2014; 94(7):806-17; PMID:24862967; http://dx.doi.org/10.1038/labinvest.2014.61
13. D.Verhelle, L.G.Corral, K.Wong, J.H.Mueller, L.Moutouh-de Parseval, K.Jensen-Pergakes, P.H.Schafer, R.Chen, E.Glezer, G.D.Ferguson et al., Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67(2):746-55; PMID:17234786; http://dx.doi.org/10.1158/0008-5472.CAN-06-2317
14. G.Gorgun, E.Calabrese, E.Soydan, T.Hideshima, G.Perrone, M.Bandi, D.Cirstea, L.Santo, Y.Hu, Y.T.Tai et al., Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010; 116 (17):3227-37; PMID:20651070; http://dx.doi.org/10.1182/blood-2010-04-279893
15. I.Breitkreutz, M.S.Raab, S.Vallet, T.Hideshima, N.Raje, C.Mitsiades, D.Chauhan, Y.Okawa, N.C.Munshi, P.G.Richardson et al., Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22(10):1925-32; PMID:18596740; http://dx.doi.org/10.1038/leu.2008.174
16. A.G.Ramsay, A.J.Johnson, A.M.Lee, G.Gorgün, R.Le Dieu, W.Blum, J.C.Byrd, J.G.Gribben. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118(7):2427-37; PMID:18551193
17. A.G.Ramsay, A.J.Clear, R.Fatah, J.G.Gribben. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012; 120 (7):1412-21; PMID:22547582; http://dx.doi.org/10.1182/blood-2012-02-411678
18. C.Galustian, B.Meyer, M.C.Labarthe, K.Dredge, D.Klaschka, J.Henry, S.Todryk, R.Chen, G.Muller, D.Stirling et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58(7):1033-45; PMID:19009291; http://dx.doi.org/10.1007/s00262-008-0620-4
19. E.Kneppers, B.van der Holt, M.J.Kersten, S.Zweegman, E.Meijer, G.Huls, J.J.Cornelissen, J.J.Janssen, C.Huisman, P.B.Cornelisse et al., Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.Blood 2011; 118(9):2413-9; PMID:21690556; http://dx.doi.org/10.1182/blood-2011-04-348292
20. I.Sakamaki, L.W.Kwak, S.C.Cha, Q.Yi, B.Lerman, J.Chen, S.Surapaneni, S.Bateman, H.Qin. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 2014; 28(2):329-37; PMID:23765229; http://dx.doi.org/10.1038/leu.2013.177
21. P.A.Haslett, W.A.Hanekom, G.Muller, G.Kaplan. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187 (6):946-55; PMID:12660941; http://dx.doi.org/10.1086/368126
22. R.A.Franklin, A.Tordai, H.Patel, A.M.Gardner, G.L.Johnson, E.W.Gelfand. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 1994; 93(5):2134-40; PMID:8182145; http://dx.doi.org/10.1172/JCI117209
23. J.M.Marchingo, A.Kan, R.M.Sutherland, K.R.Duffy, C.J.Wellard, G.T.Belz, A.M.Lew, M.R.Dowling, S.Heinzel, P.D.Hodgkin. T cell signaling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. Science 2014; 346(6213):1123-7; PMID:25430770; http://dx.doi.org/10.1126/science.1260044
24. B.G.Till, M.C.Jensen, J.Wang, X.Qian, A.K.Gopal, D.G.Maloney, C.G.Lindgren, Y.Lin et al., CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119(17):3940-50; PMID:22308288; http://dx.doi.org/10.1182/blood-2011-10-387969
25. E.Q.Han, X.L.Li, C.R.Wang, T.F.Li, S.Y.Han. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 2013; 6:47; PMID:23829929; http://dx.doi.org/10.1186/1756-8722-6-47